← Back to Search

Polysaccharide

Rhamnan Sulfate for Cardiovascular Health

N/A

Recruiting

Research Sponsored by University of Texas at Austin

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up after the 3-week intervention

Awards & highlights

Study Summary

This trial will test if a short-term supplement can reduce risk factors for heart disease in adults with risk factors.

Who is the study for?

This trial is for middle-aged and older adults who have a BMI of less than 40 kg/m2 and at least one risk factor for cardiovascular disease, such as high cholesterol, high blood pressure, obesity, or higher-than-normal fasting glucose levels. It's not suitable for pregnant or breastfeeding individuals, those with alcohol abuse issues, gastrointestinal or kidney diseases, or those engaging in strenuous physical activity more than three times a week.Check my eligibility

What is being tested?

The study is testing whether taking rhamnan sulfate (a substance derived from seaweed) can improve markers that indicate how well blood vessels are functioning in people at risk of cardiovascular disease. Participants will supplement their diet with this compound over a short period to see if it has beneficial effects on vascular health.See study design

What are the potential side effects?

Potential side effects are not explicitly listed but could include digestive disturbances due to the introduction of a new dietary supplement. As always with clinical trials involving supplements, there may be risks that are currently unknown.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ after the 3-week intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~after the 3-week intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and after the 3-week intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Vascular function

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Rhamnan sulfateExperimental Treatment1 Intervention

The subjects will take rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.

Group II: PlaceboPlacebo Group1 Intervention

The subjects will take placebo (Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Texas at AustinLead Sponsor

353 Previous Clinical Trials

81,229 Total Patients Enrolled

Konan Chemical ManufacturingUNKNOWN

Media Library

Rhamnan Sulfate (Polysaccharide) Clinical Trial Eligibility Overview. Trial Name: NCT05651230 — N/A

Cardiovascular Disease Research Study Groups: Rhamnan sulfate, Placebo

Cardiovascular Disease Clinical Trial 2023: Rhamnan Sulfate Highlights & Side Effects. Trial Name: NCT05651230 — N/A

Rhamnan Sulfate (Polysaccharide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05651230 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are octogenarians eligible to enrol in this research?

"This clinical trial has a restricted age range of 35 to 85. In contrast, there are 27 trials for minors and 378 specifically tailored towards elderly patients."

Answered by AI

Are additional participants needed for this exploration?

"Unfortunately, the data on clinicaltrials.gov implies that this particular medical study is not recruiting new participants at the moment; it was initially posted in January of 2023, and had its last update in December of 2022. However, there are 423 other trials actively searching for patients currently."

Answered by AI

Are my characteristics compatible with the criteria for participation in this research project?

"This clinical evaluation is accepting 15 individuals with cardiovascular conditions who are between 35 and 85 years old. To qualify, applicants should have a BMI of less than 40 kg/m2 and evidence of at least one cardiac risk factor such as hypertension, dyslipidemia, obesity, or impaired fasting glucose."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Seaweed-derived Rhamnan Sulfate and Vascular Function

2023. "Seaweed-derived Rhamnan Sulfate and Vascular Function". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05651230.